A Phase 3 interventional study of Ligelizumab 120 mg and Ligelizumab 240 mg in Food Allergy, sponsored by Novartis Pharmaceuticals. Terminated at 49 sites in 9 countries. Open to participants aged 6 Years to 57 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Food Hypersensitivity with a site in United States — 19 open to participants now, 28 under way, 3 of them phase 3. Food Hypersensitivity · United States.
Among the 139 studies in Food Hypersensitivity with a site in United States, this one is the 20th largest by enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2023, is one of 7 in phase 3, and was the 118th registered.
378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.
Browse Food Hypersensitivity studies →19 of the 139 studies in Food Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:
Abigail Lang · Sites in United States
Ages 12–17
Stanford University · Sites in United States
Ages 4 mo–11 mo · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 1–30
Novartis Pharmaceuticals · Sites in United States
Ages 12–65
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12 mo–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 40 (77%) stop at 75 or younger; 44 take children under 18; 17 take healthy volunteers.
This study: 6 Years to 57 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 49 · Phase 3 7 · Phase 4 3
First in 1996; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 60 across 248 interventional studies indexed under Food Hypersensitivity.
Median enrollment 41 across the 105 interventional studies, 270 across the 33 observational. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 139 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 5 studies filed under Food Hypersensitivity — fewer than ten, so there is no comparison to draw.
11 of the studies in Food Hypersensitivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT06034678Children's National Research InstituteEvaluation of The Food Allergy Mastery Program | 2026-11-30 |
| NCT04222491Massachusetts General HospitalFood Oral Immunotherapy for Peanut Allergy | 2026-12 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT05695261Rima RachidEvaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients | 2027-01-11 |
Add all 11 to your calendar (.ics) → With an account.
Among the 139 studies in Food Hypersensitivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who completed a ligelizumab Phase III study in food allergy.
This was a 3-year extension study with a 16-week follow-up period. The study enabled participants from planned multiple Phase III "core" studies to roll over to this extension study once the participants had completed predefined minimal requirements of a "core" study and agreed to consent to participate in this study.
Participants received ligelizumab treatment allocated in the core study, except for maximum responder (MR) participants performing conditional discontinuation of study treatment. Any participant considered a MR, as defined by an oral food challenge (OFC), performed conditional discontinuation of study treatment. This was to assess whether further treatment was still required because of disease modification by ligelizumab and/or a change in the underlying phenotype following the natural history of the disease (outgrowth of allergy) demonstrated by sustained unresponsiveness.
A subset of participants was offered administration of study treatment at home either by the participant him/herself (self-administration) or by parent/caregiver following training at three visits at the clinic.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ligelizumab 120 mg and matching placebo (to protect the dose blinding) every 4 weeks.
Drug: Ligelizumab 120 mg
Participants received ligelizumab 240 mg every 4 weeks.
Drug: Ligelizumab 240 mg
1 injection of 1.0 mL ligelizumab and 1 injection of 1.0 mL placebo every 4 weeks
2 injections of 1.0 mL ligelizumab every 4 weeks
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
TEAEs were defined as events where an AE either started after the first dose of extension study treatment and within 16 weeks after the last administered study treatment dose or began prior to the first dose of study treatment but increased in severity (based on preferred term) within 16 weeks after the last study treatment.
Time frame: Up to approximately 81 weeks
Number of Participants Tolerating a Single Dose of More Than or Equal to 600 mg of Peanut Protein Without Dose-Limiting Symptoms
Assessed during an open-label oral food challenge (OFC). If missing Week 52-OFC assessments, Week 156-OFC assessments were performed within 380 days (inclusive) after first extension dose date and considered as Week 52-OFC assessments.
Time frame: Up to approximately 97 weeks
Percentage of Participants With TEAEs and TESAEs, Assessed in Participants With at Least One Home Administration of Study Drug
TEAEs were defined as events where an AE either started after the first dose of extension study treatment and within 16 weeks after the last administered study treatment dose or began prior to the first dose of study treatment but increased in severity (based on preferred term) within 16 weeks after the last study treatment.
Time frame: Up to approximately 81 weeks
Change From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Teenager Form (FAQLQ-TF)
The FAQLQ-TF is a self-reported instrument designed for adolescents aged 13-17 to assess the impact of food allergy on health-related quality of life (HRQoL). The questionnaire includes three domains (emotional impact, allergen avoidance and dietary restrictions, and risk of accidental exposure). Each item was scored on a 7-point scale, with a higher score indicating greater impairment in HRQoL. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the impairment in HRQoL. OFC = oral food challenge.
Time frame: Up to approximately 97 weeks
Change From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Adult Form (FAQLQ-AF)
The FAQLQ-AF is a self-reported instrument designed for adults aged 18-55 to assess the impact of food allergy on health-related quality of life (HRQoL). The questionnaire includes four domains (emotional impact, allergen avoidance and dietary restrictions, risk of accidental exposure, and food allergy-related health). Each item was scored on a 7-point scale, with a higher score indicating greater impairment in HRQoL. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the impairment in HRQoL. OFC = oral food challenge.
Time frame: Up to approximately 97 weeks
Change From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Teenager Form (FAIM-TF)
The FAIM-TF is a self-reported instrument designed for adolescents aged 13-17. It aims to reflect the participant's perceived food allergy severity and food allergy-related risk. The questionnaire consists of six questions. The first four questions assess the participant's food allergy expectation outcomes, and the remaining two questions reflect aspects of the perceived severity of food allergy. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the perceived risk or chance of adverse events occurring. OFC = oral food challenge.
Time frame: Up to approximately 97 weeks
Change From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Adult Form (FAIM-AF)
The FAIM-AF is a self-reported instrument designed for adults aged 18-55. It aims to reflect the participant's perceived food allergy severity and food allergy-related risk. The questionnaire consists of six questions; The first four questions assess the participant's food allergy expectation outcomes, and the remaining two questions reflect aspects of the perceived severity of food allergy. The total score was calculated as the arithmetic average of all completed items. the range for each item and the total score is from 1 (minimum) to 7 (maximum). The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the perceived risk or chance of adverse events occurring. OFC = oral food challenge.
Time frame: Up to approximately 97 weeks
Change From Baseline in the Medical Outcomes Study 36-item Short Form Version 2 Acute Version (SF-36v2) Physical Component Score (PCS) and Mental Component Score (MCS)
The SF-36v2 Health Survey is a 36-item instrument that measures generic health-related quality of life. It contains 8 scales and 2 component summary indices evaluating physical, social, and emotional functioning in addition to general health perceptions and mental health. PCS and MCS scores range from 0 to 100, with higher scores indicating better health outcomes.
Time frame: Up to approximately 97 weeks
| Milestone | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| Started | 81 | 82 |
| Completed | 0 | 0 |
| Not completed | 81 | 82 |
| Withdrew: Study terminated by sponsor | 76 | 76 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Guardian decision | 1 | 0 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Subject decision | 1 | 0 |
| Withdrew: Technical problem | 0 | 1 |
TEAEs were defined as events where an AE either started after the first dose of extension study treatment and within 16 weeks after the last administered study treatment dose or began prior to the first dose of study treatment but increased in severity (based on preferred term) within 16 weeks after the last study treatment.
| percentage of participants | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| TEAEs | 84.0 | 69.5 |
| TESAEs | 3.7 | 2.4 |
Assessed during an open-label oral food challenge (OFC). If missing Week 52-OFC assessments, Week 156-OFC assessments were performed within 380 days (inclusive) after first extension dose date and considered as Week 52-OFC assessments.
| Participants | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| Number of Participants Tolerating a Single Dose of More Than or Equal to 600 mg of Peanut Protein Without Dose-Limiting Symptoms | 1 | — |
TEAEs were defined as events where an AE either started after the first dose of extension study treatment and within 16 weeks after the last administered study treatment dose or began prior to the first dose of study treatment but increased in severity (based on preferred term) within 16 weeks after the last study treatment.
| percentage of participants | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| TEAEs | 86.1 | 67.4 |
| TESAEs | 5.6 | 0 |
The FAQLQ-TF is a self-reported instrument designed for adolescents aged 13-17 to assess the impact of food allergy on health-related quality of life (HRQoL). The questionnaire includes three domains (emotional impact, allergen avoidance and dietary restrictions, and risk of accidental exposure). Each item was scored on a 7-point scale, with a higher score indicating greater impairment in HRQoL. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the impairment in HRQoL. OFC = oral food challenge.
| Unit on a scale | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| Change From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Teenager Form (FAQLQ-TF) | — | 1.13 ± NA |
The FAQLQ-AF is a self-reported instrument designed for adults aged 18-55 to assess the impact of food allergy on health-related quality of life (HRQoL). The questionnaire includes four domains (emotional impact, allergen avoidance and dietary restrictions, risk of accidental exposure, and food allergy-related health). Each item was scored on a 7-point scale, with a higher score indicating greater impairment in HRQoL. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the impairment in HRQoL. OFC = oral food challenge.
| Unit on a scale | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| Change From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Adult Form (FAQLQ-AF) | 0.32 ± 0.873 | 0.29 ± 1.048 |
The FAIM-TF is a self-reported instrument designed for adolescents aged 13-17. It aims to reflect the participant's perceived food allergy severity and food allergy-related risk. The questionnaire consists of six questions. The first four questions assess the participant's food allergy expectation outcomes, and the remaining two questions reflect aspects of the perceived severity of food allergy. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the perceived risk or chance of adverse events occurring. OFC = oral food challenge.
| Unit on a scale | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| Change From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Teenager Form (FAIM-TF) | — | 0.33 ± NA |
The FAIM-AF is a self-reported instrument designed for adults aged 18-55. It aims to reflect the participant's perceived food allergy severity and food allergy-related risk. The questionnaire consists of six questions; The first four questions assess the participant's food allergy expectation outcomes, and the remaining two questions reflect aspects of the perceived severity of food allergy. The total score was calculated as the arithmetic average of all completed items. the range for each item and the total score is from 1 (minimum) to 7 (maximum). The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the perceived risk or chance of adverse events occurring. OFC = oral food challenge.
| Unit on a scale | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| Change From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Adult Form (FAIM-AF) | -0.44 ± 0.385 | 0.42 ± 1.296 |
The SF-36v2 Health Survey is a 36-item instrument that measures generic health-related quality of life. It contains 8 scales and 2 component summary indices evaluating physical, social, and emotional functioning in addition to general health perceptions and mental health. PCS and MCS scores range from 0 to 100, with higher scores indicating better health outcomes.
| Unit on a scale | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| PCS | 0.3 ± 5.03 | 7.0 ± 11.31 |
| MCS | 0.0 ± 6.00 | -13.0 ± 21.21 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 16 weeks post treatment, up to a maximum duration of approximately 81 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ligelizumab 120 mg | 0/81 (0%) | 3/81 (3.7%) | 47/81 (58%) |
| Ligelizumab 240 mg | 0/82 (0%) | 2/82 (2.4%) | 43/82 (52.4%) |
| Event | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| ColitisGastrointestinal disorders | 1/81 | 0/82 |
| Lip swellingGastrointestinal disorders | 1/81 | 0/82 |
| NauseaGastrointestinal disorders | 1/81 | 0/82 |
| Swollen tongueGastrointestinal disorders | 1/81 | 0/82 |
| Swelling faceGeneral disorders and administration site conditions | 1/81 | 0/82 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 1/81 | 0/82 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/81 | 0/82 |
| Pharyngeal swellingRespiratory, thoracic and mediastinal disorders | 1/81 | 0/82 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 1/81 | 0/82 |
| Pruritus allergicSkin and subcutaneous tissue disorders | 1/81 | 0/82 |
| Event | Ligelizumab 120 mg | Ligelizumab 240 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 19/81 | 17/82 |
| Injection site erythemaGeneral disorders and administration site conditions | 7/81 | 14/82 |
| HeadacheNervous system disorders | 13/81 | 5/82 |
| Upper respiratory tract infectionInfections and infestations | 12/81 | 10/82 |
| Injection site oedemaGeneral disorders and administration site conditions | 4/81 | 11/82 |
| InfluenzaInfections and infestations | 9/81 | 4/82 |
| Injection site swellingGeneral disorders and administration site conditions | 2/81 | 7/82 |
| COVID-19Infections and infestations | 6/81 | 7/82 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/81 | 3/82 |
| Injection site indurationGeneral disorders and administration site conditions | 1/81 | 6/82 |
The full analysis set (FAS) included all participants who enrolled into the extension study without screen-failure and who received at least one dose of study treatment during any core study.
| Age, Continuous(years) | Ligelizumab 120 mg | Ligelizumab 240 mg | Total |
|---|---|---|---|
| Mean | 19.4 ± 6.95 | 18.9 ± 6.23 | 19.2 ± 6.58 |
| Age, Customized(participants) | Ligelizumab 120 mg | Ligelizumab 240 mg | Total |
|---|---|---|---|
| 12 - 17 years | 41 | 46 | 87 |
| 18 - 55 years | 40 | 36 | 76 |
| Sex: Female, Male(Participants) | Ligelizumab 120 mg | Ligelizumab 240 mg | Total |
|---|---|---|---|
| Female | 37 | 36 | 73 |
| Male | 44 | 46 | 90 |
| Race/Ethnicity, Customized(participants) | Ligelizumab 120 mg | Ligelizumab 240 mg | Total |
|---|---|---|---|
| White | 58 | 61 | 119 |
| Black or African American | 4 | 4 | 8 |
| Asian | 12 | 10 | 22 |
| Multiple | 1 | 1 | 2 |
| Not Reported | 6 | 6 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2023 to primary completion in Mar 2025, 22 months.
Results were first posted in Oct 2025, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ligelizumab